Lung Cancer News

Immune-mediated Nephritis Reported to Occur with Tecentriq® (August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer (June 25, 2018)

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP... Continue Reading

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer (June 22, 2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda... Continue Reading

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers (June 4, 2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About... Continue Reading

Smoking and Cancer: Understand the Risk and What You Can Do to Control It (May 8, 2018)

CancerConnect News: Smoking tobacco cigarettes is responsible for drastically increasing the risk of the developing lung cancer— the number-one cause of cancer-related deaths in the U.S—as well as several other types of cancer (not to mention additional... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (April 11, 2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading

Managing Side Effects From EGFR Inhibitors (April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

E-cigarettes May Help Adults Switch From Cigarettes but Encourage Smoking in Teens (February 1, 2018)

By AMERICAN HEART ASSOCIATION NEWS CancerConnect News: E-cigarettes can be highly addictive, and kids who use them are more likely to start smoking regular cigarettes, concluded a panel of public health experts. A report released this week by the National... Continue Reading

Latest Lung Cancer News By Stage


General Lung Cancer

Sorry, there are no articles available for this cancer stage.

More General Lung Cancer